Chemotherapy Induced Peripheral Neuropathy Market Scope, Analysis, and Trends by 2028
Chemotherapy Induced Peripheral Neuropathy Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 813.48 Million |
| Market Size by 2028 | US$ 1,174.26 Million |
| Global CAGR (2021 - 2028) | 5.4% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
By Geography
Based on geography, the chemotherapy induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Company Profiles
- Regenacy Pharmaceuticals, Inc.
- Asahi Kasei Pharma Corporation
- Novaremed
- Makscientific, Llc
- Wex Pharmaceuticals Inc.
- Sova Pharmaceuticals, Inc.
- Kineta, Inc.
- Aptinyx Inc.
- Apexian Pharmaceuticals, Inc.
- Winsantor, Inc.
Get Free Sample For